Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer

被引:27
作者
Eisbruch, A
Thornton, AF
Urba, S
Esclamado, RM
Carroll, WR
Bradford, CR
Hazuka, MB
Littles, FJ
Strawderman, M
Wolf, GT
机构
[1] UNIV MICHIGAN,MED CTR,DEPT MED,ANN ARBOR,MI 48109
[2] UNIV MICHIGAN,MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,ANN ARBOR,MI 48109
[3] UNIV MICHIGAN,MED CTR,DEPT BIOSTAT,ANN ARBOR,MI 48109
关键词
D O I
10.1200/JCO.1996.14.8.2322
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Larynx preservation in advanced, resectable laryngeal cancer may be achieved using induction chemotherapy (CT) followed in responding patients by definitive radiation (RT). To address potential accelerated repopulation of clonogenic tumor cells during the prolonged total treatment time, we studied the feasibility of accelerated fractionated RT after CT. Methods: patients with advanced laryngeal cancer received two cycles of cisplatin 100 mg/m(2) and fluorouracil (5-Fu) 1,000 mg/m(2)/d for 5 days. Responding patients received a third cycle after which those who had complete response or tumor down-staging to T1 proceeded with accelerated RT: 70.4 Gy delivered over 5.5 weeks. patients who achieved a lesser response to CT underwent total laryngectomy and postoperative RT. Results: Thirty-three patients were accrued. Three died during the course of CT and two declined definitive treatment after CT. Twenty-one patients held a major response to CT, 20 of whom received accelerated RT. Median weight loss during RT was 11%. Late severe morbidity was observed in five patients (25%). All four patients who underwent salvage laryngectomy after accelerated RT experienced major postoperative complications, The locoregional failure rate was 25%. The larynx was preserved in 48% of the total study population and in 80% of the patients irradiated according to the study protocol. Conclusion: Accelerated RT after CT as delivered in this study may increase both acute and long-term morbidity rates compared with studies using standard RT after CT, it did nor seem to improve local/regionol tumor control or survival despite stringent patient selection criteria. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:2322 / 2330
页数:9
相关论文
共 51 条
  • [1] CONCOMITANT BOOST RADIOTHERAPY SCHEDULES IN THE TREATMENT OF CARCINOMA OF THE OROPHARYNX AND NASOPHARYNX
    ANG, KK
    PETERS, LJ
    WEBER, RS
    MAOR, MH
    MORRISON, WH
    WENDT, CD
    BROWN, BW
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06): : 1339 - 1345
  • [2] [Anonymous], 1991, NEW ENGL J MED, V324, P1685
  • [3] [Anonymous], 1986, EUR J SURG ONCOL, V12, P289
  • [4] BEAUDUIN VGM, 1991, J CLIN ONCOL, V9, P1385
  • [5] BEGG AC, 1992, SEMIN RADIAT ONCOL, V2, P22
  • [6] BOURHIS J, 1994, LARYNGOSCOPE, V104, P468
  • [7] OVEREXPRESSION OF P53 PREDICTS ORGAN PRESERVATION USING INDUCTION CHEMOTHERAPY AND RADIATION IN PATIENTS WITH ADVANCED LARYNGEAL-CANCER
    BRADFORD, CR
    ZHU, SB
    WOLF, GT
    POORE, J
    FISHER, SG
    BEALS, T
    MCCLATCHEY, KD
    CAREY, TE
    HONG, WK
    URBA, S
    ENDICOTT, JW
    CLOSE, L
    FISHER, SR
    TOOHILL, RJ
    KARP, D
    MILLER, DM
    CHEUNG, NK
    WEAVER, A
    HILLEL, AD
    SPAULDING, M
    CHANG, BK
    DOUGHERTY, B
    DECONTI, R
    GAREWAL, H
    FYE, C
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1995, 113 (04) : 408 - 412
  • [8] A FEASIBILITY STUDY OF CONCOMITANT BOOST RADIOTHERAPY FOR PATIENTS WITH CANCER OF THE SUPRAGLOTTIC LARYNX
    BUJKO, K
    SKOCZYLAS, JZ
    BENTZEN, SM
    HLINIAK, A
    WASILEWSKI, M
    SZUTKOWSKI, ZJ
    OSMOLSKI, A
    [J]. ACTA ONCOLOGICA, 1993, 32 (06) : 637 - 640
  • [9] PRIMARY SITE MANAGEMENT FOLLOWING INDUCTION CHEMOTHERAPY WITH CISPLATINUM, 5-FLUOROURACIL, AND LEUCOVORIN
    BUSSE, PM
    CLARK, JR
    BEARD, CJ
    DREYFUSS, AI
    LUCARINI, JW
    ROSSI, R
    CASEY, D
    NORRIS, CM
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1993, 15 (05): : 413 - 418
  • [10] CROLL GA, 1989, EUR J SURG ONCOL, V15, P350